Genetic testing for Stargardt macular dystrophy

Abeshi A., Zulian A., Beccari T., DÜNDAR M., D'Esposito F., Bertelli M.

EUROBIOTECH JOURNAL, cilt.1, ss.105-107, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.24190/issn2564-615x/2017/s1.33
  • Dergi Adı: EUROBIOTECH JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.105-107
  • Erciyes Üniversitesi Adresli: Evet

Özet

We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for Stargardt macular dystrophy (STGD). STGD is mostly inherited in an autosomal recessive manner and rarely in an autosomal dominant manner, with an overall prevalence of 1-5 per 10 000 live births. It is caused by variations in the ABCA4, CNGB3, ELOVL4, PRPH2 and PROM1 genes. Clinical diagnosis is based on ophthalmological examination, fluorescein angiography, electroretinography, visual field testing, optical coherence tomography and color testing. The genetic test is useful for confirming diagnosis, and for differential diagnosis, couple risk assessment and access to clinical trials.